Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02562768 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT02562768 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 80 participants.
The verdict
NCT02562768, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This two-part study will evaluate how safe LY3154207 is and the effects it has on the body. Part A will include healthy participants. Each participant will receive daily doses of LY3154207 or placebo for 14 days. Part A will last approximately 4 weeks including a 17 day stay in the clinical research unit (CRU) and follow-up. Part B is contingent on the results of Part A. Part B will include participants with Parkinson's disease. Each participant will receive daily doses of LY3154207 or placebo for 14 days. Part B will last approximately 4 weeks including a 17 day stay in the CRU and follow-up. Both Part A and Part B will require screening within 30 days prior to the start of the study.
Interventions
- DRUG Placebo
- DRUG LY3154207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-09-30 |
| Est. Completion | 2017-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02562768
The ClinicalTrials.gov registry entry for NCT02562768 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02562768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02562768 about?
NCT02562768 is a clinical study titled "A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease". This two-part study will evaluate how safe LY3154207 is and the effects it has on the body. Part A will include healthy participants. Each participant will receive daily doses of LY3154207 or placebo for 14 days. Part A will last approximately 4 weeks including a 17 day stay in the clinical researc...
What is the current status of trial NCT02562768?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2015-09-30. Estimated completion is 2017-03-03.
What interventions are being tested in trial NCT02562768?
The interventions under investigation include: Placebo (DRUG), LY3154207 (DRUG).
Who is sponsoring clinical trial NCT02562768?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.